Welcome to CannaTech UK, Britain’s First Ever Medical Cannabis Summit
We are pleased to announce CannaTech UK, Britain’s first-ever international Summit for Accelerating Cannabis Innovation curated specifically for the UK and European markets.
Join innovative researchers and scientists, pharma experts, regulators, investors, and entrepreneurs as they share their knowledge about the burgeoning medical cannabis industry. The main event will take place October 26 at The Old Truman Brewery. The Summit will focus on discussions by the world’s leading names and industry experts in the cannabis and cannabis start-up spheres.
The main event on 26 October will cover the European cannabis market, cannaceuticals, CBD, regulatory issues facing both the UK and Europe and more. Economists foresee the potential overall cannabis and cannabis-related product market reaching the tens of billions of dollars in the next decade. CannaTech will host a pre-event Investor Symposium on October 25 that will be dedicated to understanding the ins-and-outs of investing in the cannabis industry. The investor symposium only event is almost at capacity.
CannaTech UK speakers will include:
Chuck Rifici, CEO of Nesta Holding Co, a private equity firm that builds partnerships and brands within the cannabis space. Mr. Rifici is the founder of Canada’s Canopy Growth, the world’s leading diversified cannabis company now worth over 1 billion USD.
Prof. Michael Barnes an internationally recognized, senior neurologist and consultant in rehabilitation medicine with vast expertise in medical cannabis. Prof. Barnes is a leading voice in the UK calling to change cannabis laws to help patients in need.
Dr. William Levine, founder of CannRx, a leader in the development of medical applications for the cannabis plant. CannRx is a subsidiary of Izun Pharmaceuticals, an Israeli biopharmaceutical company, specializing in validated assays and cannabis delivery methods. The company is developing a rapid testing kit to qualitatively analyze specific cannabinoids in plants.
Constance Finley, founder of Constance Therapeutics, a San Francisco Bay Areavertically integrated medicinal cannabis company producing standardized and science-based whole-plant cannabis extracts, filling the gap between traditional pharmaceuticals and more commonplace cannabis products. Constance Therapeutics deal with patients on a one-on-one basis providing physicians and their patients expanded treatment options for a range of ailments.
Neil Mahapatra, Managing Partner of Kingsley Capital Partners, a UK based investment firm. Kingsley is the only investment firm outside of the U.S. to take a global approach to the legalized cannabis market and has founded two cannabis operating companies: Forma Holdings and Oxford Cannabinoid Technologies.
Tracy Ryan, CEO and lead consultant for the California-based cannabis collective CannaKids, leaders in cannabinoid therapies for children and adults based on internationally compiled scientific research.
Jason Reed, Executive Director of LEAP UK. LEAP stands for Law Enforcement Against Prohibition. Its goal is to reduce the multitude of unintended harmful consequences resulting from fighting the war on drugs and lessen the incidence of death, disease, crime, and addiction by ultimately ending drug prohibition.
Lorne Gertner, co-founder and former chairman of PharmaCan Capital (now Cronos Group), a holding company that acquires or buys minority positions in licensed Canadian cannabis producers and co-founder of Tokyo Smoke, a retail operation and brand that sells cannabis paraphernalia and accessories.
Topics will include:
“The Rise of the Cannaceutical”, “A Comprehensive Overview on the State of Medical Cannabis in Europe” and “What Every Investor Needs to Know About the Regulatory Environment.”
Explaining why CannaTech has chosen Britain, Saul Kaye, Founder & CEO of iCAN: israel-cannabis said, “London is the financial capital of the world and a gateway to Europe, despite Brexit.
“The MRHA and regulators are starting to see the need for better regulation that reflects the current social and medical status of cannabis, yet they are moving slower than pretty much everyone else out there.”
“Interest from UK investors in the sector is at an all-time high. Mothers are outraged over the lack of access to products for epilepsy, pain, and cancer treatments. As we have seen in other countries this is one of the biggest drivers towards better access for patients.”
To learn more about the CannaTech UK Innovation Summit, purchase tickets and subscribe to event updates and speakers lists click here.
To learn about iCAN, the Summit’s organizers, click here.
For further information, to RSVP and to arrange interviews with the conference organizers and speakers, contact:
Laura Kam, email@example.com +972-54-806-8613